美国成人每十年接种破伤风类毒素、减量白喉类毒素和无细胞百日咳疫苗(Tdap)的经济影响
研究使用静态队列模型评估美国≥21岁成人以Tdap替代Td每十年加强免疫的经济学影响。在百日咳低发病率(2.5例/10万人年)时每避免一例成本为111,540美元、每获得一个QALY成本为8,972,848美元;随着发病率升高至500例/10万人年,每避免一例和每QALY成本分别降至427美元和35,474美元。作者认为基于报告病例,替代策略每QALY成本高,但未考虑项目便利性,若真实发病率高于监测报告,则可能带来中度成本效果改善。
要点
- 在百日咳低发病率(2.5例/10万人年)下,Tdap替代Td每避免一例成本111,540美元。
- 发病率250例/10万人年时,每避免一例和每QALY成本分别为984美元和81,678美元。
- 多因素敏感性分析中,250例/10万人年时每QALY成本范围为971至217,370美元。
核心结论
- 基于报告病例,以Tdap替代Td进行每十年加强免疫会导致较高的每QALY成本;但未考虑项目因素,且若百日咳真实发病率高于国家监测报告,替代可能带来病例和每QALY成本的中度下降。
研究设计与样本
- 采用静态队列模型,评估在4,386,854名≥21岁成人终生期间以Tdap替代Td的影响;因百日咳诊断不足且真实发病率未知,将发病率从2.5例/10万人年变化至500例/10万人年;疫苗和医疗费用来自索赔数据;对疫苗有效性、保护持续时间、疫苗成本、疾病持续时间、住院率、生产力损失和缺勤进行敏感性分析;未纳入使用单一含破伤风类毒素疫苗带来的项目优势。
主要发现
- 在最低发病率估计下,接种Tdap导致每避免一例成本111,540美元、每QALY成本8,972,848美元。
- 随着发病率升高,避免病例数增加,每QALY成本迅速下降;发病率250例/10万人年时每避免一例和每QALY成本分别为984美元和81,678美元;500例/10万人年时分别为427美元和35,474美元。
- 在多因素敏感性分析中,假设发病率250例/10万人年,每QALY成本估计范围为971美元(最有利)至217,370美元(最不利)。
关键数值与推荐
- 美国推荐≥11岁人群接种一剂Tdap,随后每十年接种破伤风和白喉类毒素(Td)加强剂;许多提供者使用Tdap替代Td。
- 研究设定的百日咳发病率范围为2.5例/10万人年至500例/10万人年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 百日咳诊断不足且真实发病率未知。
- 未纳入使用单一含破伤风类毒素疫苗带来的项目优势。
- 百日咳发病率测量不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the United States, persons ≥11 years are recommended to receive one dose of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine, followed by decennial tetanus- and diphtheria-toxoid (Td) boosters. Many providers use Tdap instead of Td. We evaluated epidemiologic and economic impacts of replacing Td boosters with Tdap. METHODS: We used a static cohort model to examine replacing Td with Tdap over the lifetime of 4,386,854 adults ≥21 years. Because pertussis is underdiagnosed and true incidence is unknown, we varied incidence from 2.5 cases/100,000 person-years to 500 cases/100,000 person-years. We calculated vaccine and medical costs from claims data. We estimated cost per case prevented and per quality-adjusted life year (QALY) saved; sensitivity analyses were conducted on vaccine effectiveness (VE), protection duration, vaccine cost, disease duration, hospitalization rates, productivity loss and missed work. We did not include programmatic advantages resulting from use of a single tetanus-toxoid containing vaccine. RESULTS: At lowest incidence estimates, administering Tdap resulted in high costs per averted case ($111,540) and QALY saved ($8,972,848). As incidence increased, cases averted increased and cost per QALY saved decreased rapidly. With incidence estimates of 250 cases/100,000 person-years, cost per averted case and QALY saved were $984 and $81,678 respectively; at 500 cases/100,000 person-years, these values were $427 and $35,474. In multivariate sensitivity analyses, assuming 250 cases/100,000 person-years, estimated cost per QALY saved ranged from $971 (most favorable) to $217,370 (least favorable). CONCLUSIONS: Our findings suggest that replacing Td with Tdap for the decennial booster would result in high cost per QALY saved based on reported cases. However, programmatic considerations were not accounted for, and if pertussis incidence, which is incompletely measured, is assumed to be higher than reported through national surveillance, substituting Tdap for Td may lead to moderate decreases in pertussis cases and cost per QALY.
引用
- Havers FP, Cho BH, Walker JW, et al. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States. Vaccine. 2019. PMID: 31676198. doi:10.1016/j.vaccine.2019.09.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。